Study #2023-0248
Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipients. A multi-center, observational trial.
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Lung Disease;Hematopoietic Cell Transplantation;Graft Versus Host Disease
Study phase:
Physician name:
Ajay Sheshadri
Department:
Pulmonary Medicine
For general questions about clinical trials:
1-844-511-1657
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.